Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

Antiviral Agents / therapeutic use Arthritis, Rheumatoid / diagnosis Biological Products / therapeutic use Female Hepatitis B Surface Antigens / drug effects Hepatitis B virus / physiology Humans Immunocompromised Host Immunosuppressive Agents / therapeutic use Inflammatory Bowel Diseases / diagnosis Male Mass Screening Prevalence Prognosis Risk Assessment Survival Analysis Virus Activation / drug effects
Anti-CD20 Direct-acting antivirals Hepatitis B Inflammatory bowel diseases Reactivation Rheumatoid arthritis

Journal

Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002

Informations de publication

Date de publication:
08 2019
Historique:
entrez: 4 7 2019
pubmed: 4 7 2019
medline: 9 4 2020
Statut: ppublish

Résumé

Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.

Identifiants

DOI: 10.1016/j.cld.2019.04.012 PMID: 31266625
pubmed: 31266625
pii: S1089-3261(19)30025-X
doi: 10.1016/j.cld.2019.04.012
pii:
doi:

Substances chimiques

Antiviral Agents 0
Biological Products 0
Hepatitis B Surface Antigens 0
Immunosuppressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

521-534

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Joe Sasadeusz (J)

Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia; University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia. Electronic address: j.sasadeusz@mh.org.au.

Andrew Grigg (A)

Olivia Newton John Cancer Research Institute, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

Peter D Hughes (PD)

University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia.

Seng Lee Lim (S)

National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore.

Michaela Lucas (M)

University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia.

Geoff McColl (G)

University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia.

Sue Anne McLachlan (SA)

St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.

Marion G Peters (MG)

University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA.

Nicholas Shackel (N)

Ingham Institute, 1 Campbell Street, Liverpool, Sydney, North South Wales 2170, Australia.

Monica Slavin (M)

Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia; Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia.

Vijaya Sundararajan (V)

University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia; Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia.

Alexander Thompson (A)

University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.

Joseph Doyle (J)

The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia; Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia.

James Rickard (J)

Olivia Newton John Cancer Research Institute, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia.

Peter De Cruz (P)

University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia.

Robert G Gish (RG)

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA.

Kumar Visvanathan (K)

University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia; St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Polyarthrite rhumatoïde › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes de surface du virus de l'hépatite B › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Virus › Virus de l'hépatite › Hepadnaviridae › Orthohepadnavirus › Virus de l'hépatite B › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Phénomènes du système immunitaire › Sujet immunodéprimé › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Dépistage de masse › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Diagnostic › Pronostic › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Screening and Prophylaxis to Prevent Hepatitis...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Activation virale › Screening and Prophylaxis to Prevent Hepatitis...